+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 1Year - 17Years
All Genders
ID05609630

Evaluation of Upadacitinib and Tocilizumab Treatments in Children and Adolescents With Active Systemic Juvenile Idiopathic Arthritis

Led by AbbVie · Updated on 2026-09-15

90

Participants Needed

45

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate how safe and effective upadacitinib is in treating children and adolescents aged 1 to under 18 years with active systemic juvenile idiopathic arthritis sJIA, a severe form of juvenile arthritis that can affect joints and other organs like the liver and heart. The study includes a comparison group receiving tocilizumab, another treatment option, to assess changes in disease activity and adverse events. sJIA is a lifelong condition that can be challenging to manage, making this study important for improving treatment options. Participants are assigned to one of two groups Cohort 1 receives either upadacitinib or tocilizumab, while Cohort 2 receives upadacitinib alone. Upadacitinib is given as oral tablets once daily or oral solution twice daily, and tocilizumab is administered by subcutaneous injection or intravenous infusion following local guidelines. Treatment lasts for 52 weeks, followed by a 30-day safety follow-up period. The study involves about 90 participants across approximately 45 sites worldwide. During the study, participants will attend regular visits or calls at hospitals or clinics where medical assessments will be performed to monitor treatment effects and side effects. Researchers will collect information through questionnaires and clinical evaluations, including measuring the number of active joints, disease activity scores, and inflammation markers. The main outcomes focus on the percentage of participants showing improvement by week 12 and recording any adverse events up to week 52, with ongoing safety monitoring throughout the study.

CONDITIONS

Brief Title

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here